BRIACELL THERAPEUTICS BCTXF news, videos and press releases
For more news please use our advanced search feature.
BRIACELL THERAPEUTICS BCTXF - More news...
BRIACELL THERAPEUTICS BCTXF - More news...
- BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting
- BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™
- BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
- BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
- BriaCell Provides Update on Remarkable Responder
- BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
- BriaCell Completes Share Consolidation
- BriaCell Therapeutics Corp. Announces Share Consolidation
- BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
- BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
- BriaCell Announces Voting Results of the Special Meeting of Shareholders
- BriaCell Announces Closing of Non-Brokered Private Placement of $568,444
- BriaCell Therapeutics Corp. to File Amendment to Management Information Circular
- BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
- BriaCell Therapeutics Corp. to Clarify Record Date
- Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
- BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
- BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
- BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
- BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
- BriaCell Appoints Richard J. Berman to Board of Directors
- BriaCell Announces $350,000 Equity Investment by Board of Directors
- BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
- BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
- BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
- BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
- BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
- BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
